New You (NWYU) 10-Q20 Oct 142015 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Aug. 31, 2014	Oct. 20, 2014
Document And Entity Information	'	'
Entity Registrant Name	'RADIANT CREATIONS GROUP, INC.	'
Entity Central Index Key	'0001372184	'
Document Type	'10-Q	'
Document Period End Date	31-Aug-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--02-28	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	36,233,708
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2015	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Aug. 31, 2014	Feb. 28, 2014
ASSETS	'	'
Cash	$4,756	$120,875
Accounts receivable	'	51,045
Accounts receivable reserve	146,129	72,182
Inventory	68,153	64,701
Prepaid expenses	7,400	8,410
Total current assets	226,438	317,213
Fixed assets, net	9,835	8,968
Total assets	236,273	326,181
CURRENT LIABILITIES:	'	'
Accounts payable and accrued liabilities	20,806	16,828
Accrued interest	115,846	74,358
Notes payable - related party	14,063	65,650
Notes payable	90,000	95,000
Convertible notes payable, current portion	476,150	513,500
Derivative liabilities	191,743	'
Total current liabilities	908,608	765,336
LONG-TERM LIABILITIES:	'	'
Convertible notes payable, net of current portion and discount of $335,635	366,901	730,448
Total liabilities	1,275,509	1,495,784
STOCKHOLDERS' DEFICIT	'	'
Common stock at $0.001 par value:100,000,000 shares authorized; 56,233,708 and 54,271,336 shares issued and outstanding, respectively	562	543
Additional paid-in capital	6,240,032	3,650,743
Accumulated deficit	-7,279,830	-4,820,889
Total stockholders' deficit	-1,039,236	-1,169,603
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$236,273	$326,181

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Aug. 31, 2014	Feb. 28, 2014
Statement of Financial Position [Abstract]	'	'
Common stock, share authorised	100,000,000	100,000,000
Common stock, par value	$0.00	$0.00
Common stock, share issued	56,233,708	54,271,336
Common stock, share outstanding	56,233,708	54,271,336
Net of current portion and discount	$335,635	$335,635

Condensed_Consolidated_Stateme

Condensed Consolidated Statement Of Operations (USD $)	3 Months Ended		6 Months Ended
Condensed Consolidated Statement Of Operations (USD $)	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014	Aug. 31, 2013
Income Statement [Abstract]	'	'	'	'
NET REVENUES	$37,905	$37,672	$408,456	$37,672
COST OF SERVICES	6,652	35,281	36,202	35,281
GROSS PROFIT	31,253	2,391	372,254	2,391
OPERATING EXPENSES:	'	'	'	'
General and administrative expenses	739,709	621,560	3,054,953	629,377
Depreciation	450	150	900	150
Inventory write-off	'	24,899	3,676	24,899
Total operating expenses	740,159	646,609	3,059,529	654,426
Operating income (loss)	-708,906	-644,218	-2,687,275	-652,035
OTHER INCOME (EXPENSES):	'	'	'	'
Recovery of bad debt	'	'	195,535	'
Interest expense	196,987	181,303	247,244	209,281
Gain (loss) on derivative liability	344,083	-205,963	280,043	-205,963
Total other income (expenses)	147,096	-387,266	228,334	-415,244
NET LOSS	($561,810)	($1,031,484)	($2,458,941)	($1,067,279)
NET LOSS PER COMMON SHARE - Basic and Diluted	($0.01)	($0.01)	($0.03)	($0.01)
Weighted Common Shares Outstanding - Basic and Diluted	54,400,221	32,097,540	54,838,863	32,097,540

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement Of Cash Flows (USD $)	6 Months Ended
Condensed Consolidated Statement Of Cash Flows (USD $)	Aug. 31, 2014	Aug. 31, 2013
CASH FLOWS PROVIDED BY (USED) IN OPERATING ACTIVTIES:	'	'
Net loss	($2,458,941)	($1,067,279)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation expense	900	150
Inventory write off	3,676	24,899
(Gain) Loss on derivative liability	280,043	-205,963
Amortization of debt discount	178,543	153,557
Stock compensation expense	2,488,416	564,627
Changes in operating assets and liabilities:	'	'
Inventory	7,128	'
Accounts receivable	-51,045	37,672
Accounts receivable reserve	73,947	'
Prepaid Expenses	-1,010	5,400
Accounts payable and accrued liabilities	45,466	61,303
Net cash provided by (used) in operating activities	-51,003	-99,852
CASH FLOWS PROVIDED BY (USED) IN INVESTING ACTIVITIES:	'	'
Purchase of fixed assets	1,767	9,255
Cash provided by (used) in investing activities	-1,767	-9,255
CASH FLOWS PROVIDED BY (USED) IN FINANCING ACTIVITIES:	'	'
Proceeds from (Payments on) related party notes	-84,499	76,000
Payment on short term notes andconvertible notes	-21,150	'
Contributed capital	'	2,000
Shares repurchased	'	-246,668
Proceeds from issuance of common stock	'	283,504
Cash provided by (used) in financing activities	-63,349	114,836
NET CHANGE IN CASH	-116,119	5,729
Cash at Beginning of Period	120,875	8,583
Cash at End of Period	4,756	14,312
SUPPLEMENTAL CASH FLOW INFORMATION	'	'
Cash paid for: Interest	68,700	'
Cash paid for: Income taxes	'	'
NON-CASH FINANCING ACTIVITY	'	'
Conversion of principal and interest into common stock	$58,500	'

Organization_And_Significant_A

Organization And Significant Accounting Policies

6 Months Ended

Aug. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Significant Accounting Policies

NOTE 1 – Organization and Significant Accounting Policies

Nature of Business

On June 20, 2013, following a change of control and subsequent acquisition of an exclusive license agreement, certain assets and processes to innovative technologies in skin protection and enhancement, which consist of various proprietary products including an anti-aging and revitalizing skin cream generally sold under the "Radiant Creations" label, the Company changed its principal business to the development and marketing of unique and proprietary scientific technologies and cosmetic and over-the-counter personal enhancement products and devices. The Company currently sells its products exclusively over the internet to customers located globally.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted

Principles of consolidation

The condensed consolidated financial statements include the accounts of the Company and its controlled subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s significant estimates include the valuation of stock-based compensation on derivatives.

Fair Value of Financial Instruments

Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as August 31, 2014:

Recurring Fair Value Measures

Level 1

Level 2

Level 3

Total

—

191,743

Embedded conversion derivative liability

Basic and diluted net loss per share

Basic loss per share is computed using the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the dilutive effects of common stock equivalents on an “as if converted” basis. For the year ended February 28, 2014, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

For the six months ended August 31, 2014, the number of potentially dilutive shares consisting of 29,204,158 shares underlying convertible debt that are not included in the calculation of diluted loss per share because their impact is anti-dilutive.

Recently issued accounting pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Going_Concern

Going Concern	6 Months Ended
Going Concern	Aug. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Going Concern	'
	NOTE 2 – Going Concern

	The accompanying financial statements have been prepared on the basis of accounting principles applicable to a “going concern”, which assume that the Company will continue in operation for at least one year and will be able to realize its assets and discharge its liabilities in the normal course of operations.

	Several conditions and events cast substantial doubt about the Company’s ability to continue as a going concern. The Company has a working capital deficit of $682,170 and has incurred net losses since inception. The Company’s future capital requirements will depend on numerous factors including, but not limited to, executing its marketing and business plans and the pursuit of business opportunities. The Company is actively pursuing alternative financing and has had discussions with various third parties, although no firm commitments have been obtained. In the interim, shareholders of the Company have committed to meeting its operating expenses. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

	These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Notes_Payable

Notes Payable	6 Months Ended
Notes Payable	Aug. 31, 2014
DisclosureShorttermConvertibleNotePayableAbstract	'
Notes Payable	'
	NOTE 3 – Notes Payable

	Notes payable – third parties

	The Company had two notes with outstanding balances as of August 31, 2014 of $75,000 and $15,000 which are subject to annual interest of 15% and mature on November 29, 2014 and January 31, 2015, respectively.

	Notes payable - related parties

	As of February 28, 2014 the Company had advances from corporate officers of $15,650. The advances were non-interest bearing and due on demand. These advances were fully paid as of August 31, 2014.

	The Company had a note payable to a related party with an outstanding balance as of August 31, 2014 of $14,063. The note is subject to annual interest of 15% and matured on August 31, 2014. At August 31, 2014 the note is default. On October 8, 2014 the Company settled the note for cash payment in the amount of $10,000.

Convertible_Notes_Payable

Convertible Notes Payable	6 Months Ended
	Aug. 31, 2014
Convertible Notes Payable	'
Convertible Notes Payable	'
	NOTE 4 – Convertible Notes Payable

	In 2013, the Company issued a convertible note to a third party amounting to $730,448 which is subject to annual interest of 10%. The note is convertible at a fixed rate of $0.075 per share and matures on September 20, 2015. Principal payments on this note during the six months ended August 31, 2014 amounted to $27,912. As disclosed above, these notes were deemed tainted on the date that the other convertible notes became convertible on May 18, 2014. A derivative liability of $252,313 was recorded as a debt discount and amortized over the term of the note.

	On November 19, 2013, the Company signed a convertible note agreement with a third party in which the party loaned $78,500 subject to annual interest of 8%. The note matured on August 21, 2014 and is convertible into the Company’s common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion. On May 18, 2014, the note became convertible and the embedded conversion option required derivative accounting owing to the variable the conversion rate. On May 18, 2014, a derivative liability of $64,146 was recorded as a debt discount and amortized over the term of the note. The embedded conversion option of the note also tainted the outstanding convertible notes. During the six months ended August 31, 2014, the lender converted $58,500 in exchange for 1,962,372 shares of common stock. The remaining balance due on the note is $20,000.

	The Company also entered into convertible note agreements with a third party on December 17, 2013 for $32,500 and January 27, 2014 for $32,500 and July 8, 2014 for $21,500. The notes are convertible after 180 days and bear similar terms to the note above. As of August 31, 2014, the notes dated December 17, 2013 and January 27, 2014 reached their conversion dates and became qualified for derivative treatment.

	Note		Face		Eligible		Conversion		Amounts		Balance Outstanding
	Date		Amount		Date		Date		Converted
	11/19/13		$	78,500	5/19/14			6/13/14	$	12,000	$	66,500
								7/1/14		12,000		54,500
								7/11/14		15,000		39,500
								7/21/14		19,500		20,000
	12/17/13		$	32,500	6/15/14			N/A		—	$	32,500
	1/27/14		$	32,500	7/26/14			N/A		—	$	32,500
	7/8/14		$	21,500	1/4/15			N/A		—	$	21,500
		Totals	$	165,000		—		—	$	58,500	$	106,500

	As of August 31, 2014, the Company owed convertible notes totaling $370,000 to third parties including accrued interest of another $4,041. Interest is 10% annually and is to be paid currently. The notes may be converted at the option of the Holder at a fixed rate of $0.075 per share. As disclosed above, these notes were deemed tainted on the date that the other note became convertible on May 18, 2014. A net derivative liability of $148,771 was recorded as a debt discount to be amortized over the terms of the notes.

	Amortization expense on the debt discounts for the six months ended August 31, 2014 amounted to $178,543.

Derivative_Liabilities

Derivative Liabilities	6 Months Ended
Derivative Liabilities	Aug. 31, 2014
Derivative Liabilities	'
Derivative Liabilities	'
	NOTE 5 – Derivative Liabilities

	The Company records the fair value of the of the conversion features of the convertible notes disclosed in Note 3 and 4 in accordance with ASC 815, Derivatives and Hedging. The fair value of the derivative liability was calculated using a multi-nominal lattice model. The fair value of the derivative liability is revalued on each balance sheet date with corresponding gains and losses recorded in the consolidated statements of operations. During the six months ended August 31, 2014, the Company recorded a gain on the change in fair value of derivative liability of $280,043.

	The following table summarizes the changes in the derivative liability during the six months ended August 31, 2014:

	Balance as of February 28, 2014		$	—
	Fair value of embedded conversion derivative liability at issuance			514,181
	Reclassification of derivatives upon conversion of convertible debt			(42,395	)
	Unrealized derivatives gains included in other expense			(280,043	)
	Ending balance as of August 31, 2014		$	191,743

	The fair value of the instruments was determined using multinomial lattice model based on the following assumptions:

		-	The projected volatility curve for each valuation period was based on the historical volatility of the Company.
		-	1 year volatility of 204%,
		-	An event of default would occur 5% of the time, increasing 1.00% per month to a maximum of 10%,
		-	The monthly trading volume would average $984,023 to $1,013,117 and would increase at 1% per month. The variable conversion price of 58% of ask-bid or close prices over 10 trading days have effective discount rates of 46.27% to 46.51%,
		-	The Note Holders would automatically convert fixed and variable conversion prices (with full ratchet resets) the notes at the stock price for the convertible Note if the registration was effective and the Company was not in default, and conversion price reset events are assumed every 3 months.

Equity

Equity	6 Months Ended
Equity	Aug. 31, 2014
Equity [Abstract]	'
Equity	'
	NOTE 5 – Equity

	During the six months ended August 31, 2014, the Company granted 38,050,000 options to employees with a term of 5 years and are exercisable at prices ranging from $0.098 to $0.127 per share. 10,000,000 options vested immediately while the remaining 28,050,000 options vest at a rate of 33% on the grant date, 33% one year from the grant date and the remaining 33% two years from the grant date. The fair value of the options was determined using a Black Scholes model. The total grant date fair value of the options amounted to $4,502,234 of which $1,840,794 was recorded as stock compensation expense during the six months ended August 31, 2014. During the six months ended August 31, 2014, the Company granted 7,500,000 warrants with a term of 5 years and are exercisable at prices ranging from $0.05 to $0.115 per share to employees and board advisors. 2,500,000 warrant vested immediately at the grant date while 2,500,000 will vest one year from the grant date and the remaining 2,500,000 warrants will vest two years from the grant date. The first tranche of the vested warrants was valued at $647,622 using the Black Scholes model and fully recognized as stock compensation expense during the six months ended August 31, 2014.
	The assumptions used in the Black Scholes valuations include:

		-	Volatility: 188% to 288%
		-	Risk-free interest rate: 0.43% to 0.58%
		-	Zero expected dividends
		-	Expected term is the simplified method
		-	Exercise prices are based on option agreements
		-	Common stock price on the valuation date
	The following tables summarize the Company’s stock options and warrants activity during the six months ended August 31, 2014:

				Options		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Weighted
				Options		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Average Remaining Life
		Balance, February 28, 2014			—	$	—
		Granted			30,550,000		0.11
		Expired			—		—
		Exercised			—		—
		Balance, August 31, 2014			30,550,000	$	0.11	$	—		16,850,000		4.54


				Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Weighted
				Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Average Remaining Life
		Balance, February 28, 2014			—	$	—
		Granted			7,500,000		0.1
		Expired			—		—
		Exercised			—		—
		Balance, August 31, 2014			7,500,000	$	0.1	$	—		2,500,000		4.67

Subsequent_Events

Subsequent Events	6 Months Ended
Subsequent Events	Aug. 31, 2014
Subsequent Events	'
Subsequent Events	'
	NOTE 7 - Subsequent Events

	On September 9, 2014, the Company signed a convertible note agreement with a third party in which the party loaned $35,000 subject to annual interest of 12%. The note is convertible into the Company’s common stock immediately upon issuance at 60% of the lowest trade price of the common stock during the 25 days preceding the date of conversion.
	On September 9, 2014 and October 13, 2014 Biodynamic Molecular Technologies, LLC (a control shareholder) agreed to cancel a total of 20,000,000 common shares of the Company. This cancellation of common stock allowed the Company to obtain additional financing without the need to expand its currently authorized number of common shares in the amount of 100,000,000.

	On September 21, 2014 the Company signed a demand promissory note with a related party in the amount of $7,500. Terms include, interest only at 10%, principle and interest due in 24 months. The note may be prepaid without notice at the option of the Company.

	On October 10, 2014, the Board of Directors agreed to designate a series of preferred shares (the Series A Super Voting Preferred Shares) including 1,000,000 (non-convertible) shares containing the following preferential provision:

	Holders of each Series A Preferred Stock shall have two hundred (200) times the number of votes on all matters submitted to the shareholders that each shareholder of the Corporation’s Common Stock (rounded to the nearest whole number) is entitled to vote at each meeting of the shareholders of the Corporation (and written actions of stockholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. Holders of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class and,

	Except as specifically provided, the Series B Preferred Stock shall, with respect to rights on redemption and rights on liquidation, winding up and dissolution, rank senior to (i) all classes of Common Stock, $0.00001 par value per share, of the Company (the “Common Stock”) and (ii) any class or series of capital stock of the Company hereafter created (unless, with the consent of the Holder(s) of Series B Preferred Stock). All other provisions remain pari passu as to the Company's common stock.

	The shares were issued to Biodynamic Molecular Technologies, LLC.

	On October 13,2014, the Board of Directors agreed to designate a series of preferred shares (the Series B Preferred Shares) including 20,000,000 (non-convertible) shares containing the following preferential provisions:

	Except as specifically provided, the Series B Preferred Stock shall, with respect to rights on redemption and rights on liquidation, winding up and dissolution, rank senior to (i) all classes of Common Stock, $0.00001 par value per share, of the Company (the “Common Stock”) and (ii) any class or series of capital stock of the Company hereafter created (unless, with the consent of the Holder(s) of Series B Preferred Stock). All other provisions remain pari passu as to the Company's common stock.

	The shares were issued to Biodynamic Molecular Technologies, LLC.

Organization_And_Significant_A1

Organization And Significant Accounting Policies (Policies)

6 Months Ended

Aug. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business

Basis of Presentation

Principles of Consolidation

Principles of consolidation

The condensed consolidated financial statements include the accounts of the Company and its controlled subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Fair Value of Financial Instruments

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as August 31, 2014:

Recurring Fair Value Measures

Level 1

Level 2

Level 3

Total

—

191,743

Embedded conversion derivative liability

Basic and Diluted Net Loss Per Share

Basic and diluted net loss per share

Recently Issued Accounting Pronouncements

Recently issued accounting pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Organization_And_Significant_A2

Organization And Significant Accounting Policies (Tables)

6 Months Ended

Aug. 31, 2014

Organization And Significant Accounting Policies Tables

Fair Value of Derivative Assets and Liabilities Measured on Recurring Basis

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as August 31, 2014:

Recurring Fair Value Measures

Level 1

Level 2

Level 3

Total

—

191,743

Embedded conversion derivative liability

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Aug. 31, 2014
Convertible Notes Payable Tables	'
Schedule of Convertible Notes Payable Conversion Dates and Derivative Treatment	'
	As of August 31, 2014, the notes dated December 17, 2013 and January 27, 2014 reached their conversion dates and became qualified for derivative treatment.

	Note		Face		Eligible		Conversion		Amounts		Balance Outstanding
	Date		Amount		Date		Date		Converted
	11/19/13		$	78,500	5/19/14			6/13/14	$	12,000	$	66,500
								7/1/14		12,000		54,500
								7/11/14		15,000		39,500
								7/21/14		19,500		20,000
	12/17/13		$	32,500	6/15/14			N/A		—	$	32,500
	1/27/14		$	32,500	7/26/14			N/A		—	$	32,500
	7/8/14		$	21,500	1/4/15			N/A		—	$	21,500
		Totals	$	165,000		—		—	$	58,500	$	106,500

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	6 Months Ended
Derivative Liabilities (Tables)	Aug. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Summary of Changes in Derivative Liabilities	'
	The following table summarizes the changes in the derivative liability during the six months ended August 31, 2014:

	Balance as of February 28, 2014	$	—
	Fair value of embedded conversion derivative liability at issuance		514,181
	Reclassification of derivatives upon conversion of convertible debt		(42,395	)
	Unrealized derivatives gains included in other expense		(280,043	)
	Ending balance as of August 31, 2014	$	191,743

Equity_Tables

Equity (Tables)	6 Months Ended
Equity (Tables)	Aug. 31, 2013
Equity Tables	'
Summary Of Stock Option Activity	'
	The following tables summarize the Company’s stock options activity during the six months ended August 31, 2014:

			Options		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Weighted
			Options		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Average Remaining Life
		Balance, February 28, 2014		—	$	—
		Granted		30,550,000		0.11
		Expired		—		—
		Exercised		—		—
		Balance, August 31, 2014		30,550,000	$	0.11	$	—		16,850,000		4.54
Summary Of Stock Warrants Activity	'The following tables summarize the Company’s warrants activity during the three months ended August 31, 2014:

			Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Weighted
			Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value		Exercisable		Average Remaining Life
		Balance, February 28, 2014		—	$	—
		Granted		7,500,000		0.1
		Expired		—		—
		Exercised		—		—
		Balance, August 31, 2014		7,500,000	$	0.1	$	—		2,500,000		4.67

Organization_And_Significant_A3

Organization And Significant Accounting Policies (Details) (USD $)	Aug. 31, 2014	Feb. 28, 2014
Recurring Fair Value Measures	'	'
Embedded conversion derivative liability	$191,743	'
Level 1	'	'
Recurring Fair Value Measures	'	'
Embedded conversion derivative liability	'	'
Level 2	'	'
Recurring Fair Value Measures	'	'
Embedded conversion derivative liability	'	'
Level 3	'	'
Recurring Fair Value Measures	'	'
Embedded conversion derivative liability	$191,743	'

Convertible_Notes_Payable_Deta

Convertible Notes Payable (Details) (USD $)

6 Months Ended

0 Months Ended

3 Months Ended

Aug. 31, 2014

Aug. 31, 2013

Jul. 21, 2014

Jul. 11, 2014

Jul. 01, 2014

Jun. 13, 2014

Nov. 19, 2013

Aug. 31, 2014

Dec. 17, 2013

Aug. 31, 2014

Jan. 27, 2014

Aug. 31, 2014

Jul. 08, 2014

Convertible Notes Payable Dated November 19, 2013

Convertible Notes Payable Dated December 17, 2013

Convertible Notes Payable Dated January 27, 2014

Convertible Notes Payable Dated July 08, 2014

Note date

19-Nov-13

17-Dec-13

27-Jan-14

8-Jul-14

Face amount

$165,000

$78,500

$32,500

$21,500

Eligible date

21-Aug-14

19-May-14

15-Jun-14

26-Jul-14

4-Jan-15

Conversion date

21-Jul-14

11-Jul-14

1-Jul-14

13-Jun-14

Amount converted

58,500

19,500

15,000

12,000

Balance outstanding

$106,500

$20,000

$39,500

$54,500

$66,500

$20,000

$32,500

$21,500

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	6 Months Ended
Derivative Liabilities (Details) (USD $)	Aug. 31, 2014
Derivative Liabilities:	'
Balance as of February 28, 2014	'
Fair value of embedded conversion derivative liability at issuance	514,181
Reclassification of derivatives upon conversion of convertible debt	-42,395
Unrealized derivatives losses included in other expense	-280,043
Ending balance as of August 31, 2014	$191,743

Equity_Summary_Of_Stock_Option

Equity (Summary Of Stock Option Activity) (Details) (USD $)	6 Months Ended
Equity (Summary Of Stock Option Activity) (Details) (USD $)	Aug. 31, 2013
Number of Options	'
Balance, February 28, 2014	'
Granted	30,550,000
Expired	'
Exercised	'
Balance, August 31, 2014	30,550,000
Weighted Average Exercise Price	'
Balance, February 28, 2014	'
Granted	$0.11
Expired	'
Exercised	'
Balance, August 31, 2014	$0.11
Aggregate Intrinsic Value	'
Exercisable	16,850,000
Weighted Average Remaining Life	'4 years 6 months 14 days

Equity_Summary_Of_Stock_Warran

Equity (Summary Of Stock Warrants Activity) (Details) (Warrants, USD $)	6 Months Ended
	Aug. 31, 2014
Warrants	'
Number Of Shares	'
Balance, February 28, 2014	'
Granted	7,500,000
Expired	'
Exercised	'
Balance, August 31, 2014	7,500,000
Weighted Average Exercise Price	'
Balance, February 28, 2014	'
Granted	$0.10
Expired	'
Exercised	'
Balance, August 31, 2014	$0.10
Aggregate Intrinsic Value	'
Exercisable	2,500,000
Weighted average remaining life	'4 years 8 months 1 day

Organization_And_Significant_A4

Organization And Significant Accounting Policies (Narrative) (Details)	6 Months Ended
	Aug. 31, 2014
Organization And Significant Accounting Policies Narrative Details	'
Antidilutive securities excluded from computation of earnings per share	29,204,158

Going_Concern_Narrative_Detail

Going Concern (Narrative) (Details) (USD $)	Aug. 31, 2014
Going Concern Narrative Details	'
Working capital deficit	$682,170

Notes_Payable_Narrative_Detail

Notes Payable (Narrative) (Details) (USD $)	Aug. 31, 2014	Feb. 28, 2014	Aug. 31, 2014	Aug. 31, 2014	Feb. 28, 2014	Aug. 31, 2014	Oct. 08, 2014
			Notes Payable - Third Parties	Notes Payable - Third Parties	Notes Payable	Notes Payable	Notes Payable
					Corporate Officers	Related Party	Related Party
							Subsequent Event
Short-term Debt [Line Items]	'	'	'	'	'	'	'
Note payable	$90,000	$95,000	$75,000	$15,000	'	'	'
Interest rate on debt	'	'	15.00%	15.00%	'	15.00%	'
Debt instrument maturity date	'	'	29-Nov-14	31-Jan-15	'	31-Aug-14	'
Notes payable - related party	14,063	65,650	'	'	15,650	14,063	'
Debt instrument terms	'	'	'	'	'	'	'

					The advances were non-interest bearing and due on demand
Payments on related party notes	'	'	'	'	'	'	$10,000

Convertible_Notes_Payable_Narr

Convertible Notes Payable (Narrative) (Details) (USD $)

6 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

Aug. 31, 2014

Aug. 31, 2013

Feb. 28, 2014

Aug. 31, 2014

Dec. 31, 2013

Nov. 19, 2013

Aug. 31, 2014

Jul. 21, 2014

Jul. 11, 2014

Jul. 01, 2014

Jun. 13, 2014

Aug. 31, 2014

Dec. 17, 2013

Aug. 31, 2014

Jan. 27, 2014

Aug. 31, 2014

Jul. 08, 2014

Convertible Notes Payable - Third Party

Convertible Notes Payable Dated November 19, 2013

Convertible Notes Payable Dated December 17, 2013

Convertible Notes Payable Dated January 27, 2014

Convertible Notes Payable Dated July 08, 2014

Common Stock

Debt Instrument [Line Items]

Debt instrument face amount

$165,000

$730,448

$78,500

$32,500

$21,500

Debt conversion price per share

$0.08

Debt instrument maturity date

20-Sep-15

21-Aug-14

19-May-14

15-Jun-14

26-Jul-14

4-Jan-15

Interest rate on debt

10.00%

8.00%

Unamortized debt discount

335,635

148,771

252,313

64,146

Repayment on notes

-84,499

76,000

-27,912

Debt instrument conversion terms

The note is convertible into the Company’s common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion.

Stock issued in conversion of debt, shares

1,962,372

Stock issued in conversion of debt, value

58,500

Convertible notes payable

106,500

370,000

20,000

39,500

54,500

66,500

32,500

21,500

Accrued interest

$115,846

$74,358

$4,041

Derivative_Liabilities_Narrati

Derivative Liabilities (Narrative) (Details)	6 Months Ended
	Aug. 31, 2014
Fair Value Assumptions - Multinomial Lattice Model:	'
Valuation model used in determining fair value of derivative liabilities	'Multinomial Lattice Model
Fair value measurement assumptions	'
	The fair value of the instruments was determined using multinomial lattice model based on the following assumptions:

		-	The projected volatility curve for each valuation period was based on the historical volatility of the Company.
		-	1 year volatility of 204%,
		-	An event of default would occur 5% of the time, increasing 1.00% per month to a maximum of 10%,
		-	The monthly trading volume would average $984,023 to $1,013,117 and would increase at 1% per month. The variable conversion price of 58% of ask-bid or close prices over 10 trading days have effective discount rates of 46.27% to 46.51%,
		-	The Note Holders would automatically convert fixed and variable conversion prices (with full ratchet resets) the notes at the stock price for the convertible Note if the registration was effective and the Company was not in default, and conversion price reset events are assumed every 3 months.
Volatility rate	204.00%

Equity_Narrative_Details

Equity (Narrative) (Details) (USD $)	6 Months Ended
Equity (Narrative) (Details) (USD $)	Aug. 31, 2014	Aug. 31, 2013
No of stock options granted	'	30,550,000
Exercise price of options	'	$0.11
Stock compensation expense	$2,488,416	$564,627
Fair value assumptions of options and warrants - Black Scholes Model	'	'
Volatility rate	204.00%	'
Minimum	'	'
Excercise price of warrants	$0.05	'
Fair value assumptions of options and warrants - Black Scholes Model	'	'
Risk Free interest rate	0.43%	'
Volatility rate	188.00%	'
Maximum	'	'
Excercise price of warrants	$0.12	'
Fair value assumptions of options and warrants - Black Scholes Model	'	'
Risk Free interest rate	0.58%	'
Volatility rate	288.00%	'
Stock Options	'	'
No of stock options granted	38,050,000	'
Stock option terms	'5 years	'
No of options vested immediately	10,000,000	'
Vesting terms of options and warrants	'	'
Vesting terms of options and warrants	10,000,000 options vested immediately while the remaining 20,550,000 options vest at a rate of 33% on the grant date, 33% one year from the grant date and the remaining 33% two years from the grant date.	'
Fair value of options vested	4,502,234	'
Stock compensation expense	1,840,794	'
Valuation model used in determining fair value of options	'Black Scholes model	'
Stock Options \| Minimum	'	'
Exercise price of options	$0.10	'
Stock Options \| Maximum	'	'
Exercise price of options	$0.13	'
Warrants	'	'
Stock option terms	'5 years	'
Vesting terms of options and warrants	'	'

	2,500,000 options vested immediately at the grant date while 2,500,000 will vest one year from the grant date and the remaining 2,500,000 warrants will vest two years from the grant date.
Stock compensation expense	$647,622	'
No of warrants vested immediately	2,500,000	'
Valuation model used in determining fair value of options	'Black Scholes model	'

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	Aug. 31, 2014	Feb. 28, 2014	Oct. 13, 2014	Oct. 10, 2014	Oct. 13, 2014	Sep. 09, 2014	Sep. 21, 2014
			Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event
			Common Stock	Series A Super Voting Preferred Stock	Series B Preferred Stock	Convertible Notes Payable Dated September 09, 2014	Promissory Note - Related Party
			Biodynamic Molecular Technologies, LLC
Debt instrument face amount	$165,000	'	'	'	'	$35,000	$7,500
Interest rate on debt	'	'	'	'	'	12.00%	10.00%
Debt instrument conversion terms	'	'	'	'	'	'	'

						The note is convertible into the Company’s common stock immediately upon issuance at 60% of the lowest trade price of the common stock during the 25 days preceding the date of conversion.
Common share authorized, shares	100,000,000	100,000,000	100,000,000	'	'	'	'
Cancellation of common shares, shares	'	'	20,000,000	'	'	'	'
Debt instrument maturity description	'	'	'	'	'	'	'

							Principle and interest due in 24 months
Preferred stock authorized, shares	'	'	'	1,000,000	20,000,000	'	'
Preferred stock voting rights	'	'	'	'	'	'	'
				Holders of each Series A Preferred Stock shall have two hundred (200) times the number of votes on all matters submitted to the shareholders that each shareholder of the Corporation’s Common Stock (rounded to the nearest whole number) is entitled to vote at each meeting of the shareholders of the Corporation (and written actions of stockholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. Holders of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class and,	Except as specifically provided, the Series B Preferred Stock shall, with respect to rights on redemption and rights on liquidation, winding up and dissolution, rank senior to (i) all classes of Common Stock, $0.00001 par value per share, of the Company (the “Common Stock”) and (ii) any class or series of capital stock of the Company hereafter created (unless, with the consent of the Holder(s) of Series B Preferred Stock). All other provisions remain pari passu as to the Company's common stock.